

# Clinical Resource Tool



Click on the links below



## Clinical Management Guidelines

**PBC: 2018 Practice Guidance from the AASLD**  
<https://tinyurl.com/AASLD-2018>



**2019: Diagnosis and Management of PBC**  
<https://tinyurl.com/ACG-2019>



**2023: Application of the Latest Advances in Evidence-Based Medicine in PBC**  
<https://tinyurl.com/kowdley>



## Patient Resources & Risk Scoring Tools



**American Liver Foundation**  
<https://tinyurl.com/ALF-PBC>



**The PBC Foundation**  
<https://www.pbcfoundation.org.uk/>



**UK-PBC Score**  
<https://tinyurl.com/UK-PBC>



**PBCers Organization**  
<https://pbcers.org/>



**GLOBE-PBC Score**  
<https://tinyurl.com/GLOBE-PBC>



## Additional Readings

### **Primary Biliary Cholangitis: Pathogenesis and Therapeutic Opportunities**

Gulamhusein AF, Hirschfield GM. *Nat Rev Gastroenterol Hepatol.* 2020;17(2):93-110.

### **Differences Between Caucasian, African American, and Hispanic Patients with Primary Biliary Cirrhosis in the United States**

Peters MG, et al. *Hepatology.* 2007;46(3):769-75.

### **A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis**

Corpechot C, et al. *N Engl J Med.* 2018;378(23):2171-2181.

### **A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis**

Nevens F, et al. *N Engl J Med.* 2016;375(7):631-43.

### **Real-World Experience with Obeticholic Acid in Patients with Primary Biliary Cholangitis**

D'Amato, D, et al. *JHEP Rep.* 2021;3(2):100248.

### **Combination of Fibrates with Obeticholic Acid is Able to Normalise Biochemical Liver Tests in Patients with Difficult-to-Treat Primary Biliary Cholangitis**

Soret PA, et al. *Aliment Pharmacol Ther.* 2021;53(10):1138-1146.